Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | AOC2 | O75106 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241437 | 0.83 | KMT2A (0.71) | KMT2ACYP3A4BAZ2BL3MBTL1RXFP1 | |
| SCHEMBL7316169 | 0.82 | KMT2A (0.69) | KMT2AL3MBTL1TSHRMAPTHPGD | |
| SCHEMBL7348821 | 0.80 | KMT2A (0.67) | KMT2ACYP3A4BAZ2BRAB9ANPC1 | |
| SCHEMBL1377974 | 0.80 | KMT2A (0.67) | KMT2ACYP3A4L3MBTL1RAB9ATSHR | |
| SCHEMBL9595456 | 0.79 | KMT2A (0.66) | KMT2ACYP3A4RAB9ANPC1TSHR | |
| SCHEMBL9593459 | 0.76 | KMT2A (0.61) | KMT2ACYP3A4L3MBTL1RAB9ANPC1 | |
| SCHEMBL92862 | 0.74 | KMT2A (0.59) | KMT2AMAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15801116 | 0.73 | KMT2A (0.58) | KMT2ACYP3A4BAZ2BL3MBTL1RXFP1 | |
| SCHEMBL371252 | 0.73 | DDAH1 (0.68) | KMT2AADAM17HPGDALDH1A1 | |
| SCHEMBL50646 | 0.72 | MAPT (0.68) | KMT2AL3MBTL1RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751149-B1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LAB (US) | 2012-06-06 | — | — | EP | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2308873-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1751149-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7098222-B2 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113551-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | KMT2A 523/4885CYP3A4 1075/4885BAZ2B 612/4885 |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | KMT2A 523/4885CYP3A4 1075/4885BAZ2B 612/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | KMT2A 939/4885CYP3A4 1107/4885BAZ2B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.